Immetas
Biotechnology company developing therapeutics that modulate innate immune pathways and inflammasome activity to treat chronic inflammation–mediated, age-associated diseases including cancers and osteoarthritis. The company uses clinically anchored, mechanism-of-action–guided discovery and advances programs spanning biologics and small molecules through translational and clinical development, often via external collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
US-11718673-B2
View Details
Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
US-11718673-B2
View DetailsProducts
Bispecific antibody therapeutic candidates targeting tumor inflammation
Pipeline candidates engineered as bispecific antibodies to modulate inflammation in the tumor microenvironment and address resistance to immune checkpoint therapies.
Preclinical intra-articular therapeutics for osteoarthritis
Local intra-articular candidate(s) aimed at controlling synovial inflammation to reduce cartilage erosion while limiting systemic adverse effects.
Bispecific antibody therapeutic candidates targeting tumor inflammation
Pipeline candidates engineered as bispecific antibodies to modulate inflammation in the tumor microenvironment and address resistance to immune checkpoint therapies.
Preclinical intra-articular therapeutics for osteoarthritis
Local intra-articular candidate(s) aimed at controlling synovial inflammation to reduce cartilage erosion while limiting systemic adverse effects.
Services
Collaborative research to combine in-house target identification and payload generation with external mRNA/LNP design and manufacturing for therapeutic candidate generation.
Collaborative research to combine in-house target identification and payload generation with external mRNA/LNP design and manufacturing for therapeutic candidate generation.
Expertise Areas
- Inflammation and innate immunity
- Inflammasome-targeted therapeutics
- Bi-specific antibody development
- mRNA and LNP therapeutics (via collaboration)
Key Technologies
- Bispecific antibody formats
- Inflammasome modulation
- mRNA therapeutics
- Lipid nanoparticle (LNP) delivery
News & Updates
Raised Series A financing of $11 million to advance research on inflammation pathways in aging and develop immune-modulating treatments for cancer and inflammatory disease; investor participation and leadership changes noted.
Research collaboration to combine in-house innate immune pathway modulation platform with external mRNA and lipid nanoparticle delivery platforms to discover mRNA therapeutics for autoimmune diseases; roles and responsibilities for each party described.
Raised Series A financing of $11 million to advance research on inflammation pathways in aging and develop immune-modulating treatments for cancer and inflammatory disease; investor participation and leadership changes noted.
Research collaboration to combine in-house innate immune pathway modulation platform with external mRNA and lipid nanoparticle delivery platforms to discover mRNA therapeutics for autoimmune diseases; roles and responsibilities for each party described.